ArticleProceedings of the National Academy of Sciences of the United States of America1992
Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 205 citations in OpenAlex.
- Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.Intensive care medicine · 2010Guideline
- The role of IGFBP-1 in the clinical prognosis and pathophysiology of acute kidney injury.American journal of physiology. Renal physiology · 2025Observational
- Insulin-like growth factor-1 effects on kidney development in preterm piglets.Pediatric research · 2024Article
- Sustained local inhibition of thrombin preserves renal microarchitecture and function after onset of acute kidney injury.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- Renal effects of growth hormone in health and in kidney disease.Pediatric nephrology (Berlin, Germany) · 2021Article
- Bioactive Compounds for the Treatment of Renal Disease.Yonsei medical journal · 2018Review
- The kidney regulates regeneration, but don't upset the balance.International urology and nephrology · 2016Review
- Renoprotective approaches and strategies in acute kidney injury.Pharmacology & therapeutics · 2016 · on this mapReview
- Cellular and Molecular Mechanisms of AKI.Journal of the American Society of Nephrology : JASN · 2016Review
- Enhanced renoprotective effect of IGF-1 modified human umbilical cord-derived mesenchymal stem cells on gentamicin-induced acute kidney injury.Scientific reports · 2016Article
- Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence.Stem cells international · 2016Review
- Renoprotective Effect of Lactoferrin against Chromium-Induced Acute Kidney Injury in Rats: Involvement of IL-18 and IGF-1 Inhibition.PloS one · 2016Article
- MicroRNA-150 deletion in mice protects kidney from myocardial infarction-induced acute kidney injury.American journal of physiology. Renal physiology · 2015Article
- Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury.American journal of physiology. Renal physiology · 2015Article
- Stromal cell-derived factor-1 (SDF1)-dependent recruitment of bone marrow-derived renal endothelium-like cells in a mouse model of acute kidney injury.The Journal of veterinary medical science · 2015Article
- Macrophage-mediated injury and repair after ischemic kidney injury.Pediatric nephrology (Berlin, Germany) · 2015Review
- Trophic Factors from Tissue Stem Cells for Renal Regeneration.Stem cells international · 2015Review
- Renal primordia activate kidney regenerative events in a rat model of progressive renal disease.PloS one · 2015Article
- Assessing intrarenal nonperfusion and vascular leakage in acute kidney injury with multinuclear (1) H/(19) F MRI and perfluorocarbon nanoparticles.Magnetic resonance in medicine · 2014Article
- Moving beyond supportive care--current status of specific therapies in pediatric acute kidney injury.Pediatric nephrology (Berlin, Germany) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The effects of administering insulin-like growth factor I (IGF-I) were examined in a model of ischemic acute tubular necrosis in rats. Injury was induced by 75 min of bilateral renal artery occlusion. Compared to rats administered vehicle, rats administered IGF-I (100 micrograms/day via continuous subcutaneous infusion) had significantly lower serum creatinine and blood urea nitrogen levels over the course of 7 days postocclusion. Glomerular filtration rate as determined by inulin clearance was examined on day 2 postocclusion and was significantly increased in IGF-I-treated animals (0.16 +/- 0.02 ml per min per 100 g of body weight) compared to vehicle-treated controls (0.08 +/- 0.02 ml per min per 100 g of body weight). The weight loss that occurred during the course of acute tubular necrosis was ameliorated by IGF-I. Mortality was reduced from 36.7% in vehicle-treated rats to 7.1% in rats administered IGF-I. Histologically, there was much less renal injury evident at day 7 postocclusion in the IGF-I-treated rats compared to vehicle-treated controls. In contrast, growth hormone (200 micrograms administered subcutaneously for 4 days) did not affect recovery of renal function or reduce mortality postreperfusion. This report demonstrates a beneficial effect of IGF-I administration in the setting of acute tubular necrosis. Several properties of IGF-I render it a pharmacological agent with excellent potential for treatment of this condition in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.